BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:19 PM
Mar 27, 2007
 |  BC Extra  |  Clinical News

MediciNova reports Phase II MS data

MediciNova (MNOV; Osaka:4875) said MN-166 missed the primary endpoint of a reduction in the cumulative number of active (Gd-enhancing (T1) and non-enhancing new/enlarging (T2)) lesions on cranial MRI scans over 12 months in a Phase II trial to treat relapsing, remitting...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >